Precision Biosciences (DTIL) Surges 2.29% – Strong 200‑Day SMA & Promising Phase I Results
Precision Biosciences (DTIL) shows a modest uptick to $6.78, backed by a 200‑day SMA lead, promising CRISPR‑based oncology trials and potential FDA approval to drive future upside.
- PRECISION BIOSCIENCES INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read